DeepMed Research

XENON PHARMACEUTICALS

🇮🇳India

Country: 🇮🇳India

Ownership: -

Established: 1996-01-01

Employees: -

Market Cap: $3.1B

Website: http://www.xenon-pharma.com/

Clinical Trials

An Open-Label Study of Azetukalner in Major Depressive Disorder

Phase 3

Conditions: Major Depressive Disorder

Interventions: Drug: Azetukalner

First Posted Date: 2025-04-10

Last Posted Date: 2025-04-10

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 460

Registration Number: NCT06922110

Locations: 🇺🇸
Chicago Research Center Inc., Chicago, Illinois, United States
🇺🇸
Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

Phase 3

Recruiting

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Azetukalner

First Posted Date: 2025-01-15

Last Posted Date: 2025-03-25

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 450

Registration Number: NCT06775379

Locations: 🇺🇸
Woodland International Research Group, Little Rock, Arkansas, United States
🇺🇸
Excell Research Inc., Oceanside, California, United States
🇺🇸
Sunwise Clinical Research, Walnut Creek, California, United States

and more 14 locations

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Phase 3

Recruiting

Conditions: Focal Onset Seizures

Interventions: Drug: XEN1101
Drug: Placebo

First Posted Date: 2023-02-08

Last Posted Date: 2025-04-08

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 360

Registration Number: NCT05716100

Locations: 🇨🇱
Centro de Investigacion Clinica UC, Santiago, Chile
🇨🇱
CINSAN, Santiago, Chile
🇨🇱
Hospital Clínico Viña del Mar, Viña Del Mar, Chile

and more 63 locations

An Open-label Study of XEN1101 in Epilepsy

Phase 3

Conditions: Focal Epilepsy
Tonic-Clonic Seizures

Interventions: Drug: XEN1101

First Posted Date: 2023-02-08

Last Posted Date: 2025-04-29

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 880

Registration Number: NCT05718817

Locations: 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇪🇸
Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
🇪🇸
Hospital Regional De Malaga, Málaga, Spain

and more 94 locations

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Phase 3

Recruiting

Conditions: Primary Generalized Tonic-Clonic Seizures

Interventions: Drug: XEN1101
Drug: Placebo

First Posted Date: 2022-12-28

Last Posted Date: 2025-04-29

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 160

Registration Number: NCT05667142

Locations: 🇧🇬
MHATNP 'Sveti Naum' EAD, Sofia, Bulgaria
🇭🇷
University Hospital Center Zagreb, Zagreb, Croatia
🇲🇽
Neurociencias Estudios Clínicos S.C, Sinaloa, Mexico

and more 126 locations

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

Phase 3

Recruiting

Conditions: Focal Onset Seizures

Interventions: Drug: XEN1101
Drug: Placebo

First Posted Date: 2022-11-14

Last Posted Date: 2025-04-29

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 360

Registration Number: NCT05614063

Locations: 🇩🇪
Universitatsklinikum Bonn, Bonn, Germany
🇪🇸
Hospital Ramón y Cajal, Madrid, Spain
🇪🇸
Hospital Ruber Internacional, Madrid, Spain

and more 127 locations

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: XEN1101 10 mg
Drug: Placebo
Drug: XEN1101 20 mg

First Posted Date: 2022-05-17

Last Posted Date: 2024-03-18

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 168

Registration Number: NCT05376150

Locations: 🇺🇸
FutureSearch Trials of Dallas, LP, Dallas, Texas, United States
🇺🇸
Neurobehavioral Research, Inc. (NBR), Cedarhurst, New York, United States
🇺🇸
Manhattan Behavioral Medicine, PLLC, New York, New York, United States

and more 16 locations

Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 14C-XEN1101

First Posted Date: 2021-07-07

Last Posted Date: 2022-01-14

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 6

Registration Number: NCT04952467

Locations: 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom

An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE

Phase 3

Terminated

Conditions: Nervous System Diseases
Epilepsy in Children
Disease
Central Nervous System Diseases
Epileptic Syndromes
Epilepsy; Seizure
Epilepsy
Brain Diseases

Interventions: Drug: XEN496

First Posted Date: 2021-06-03

Last Posted Date: 2025-02-14

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 8

Registration Number: NCT04912856

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇦🇺
Sydney Children's Hospital, Sydney, New South Wales, Australia
🇧🇪
Universitair Ziekenhuis Antwerpen - Dienst Kinderneurologie, Edegem, Antwerpen, Belgium

and more 1 locations

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

Phase 3

Terminated

Conditions: Disease
Epilepsy
Epilepsy in Children
Epilepsy; Seizure
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Epileptic Syndromes

Interventions: Drug: Placebo
Drug: XEN496

First Posted Date: 2020-11-20

Last Posted Date: 2024-08-23

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 8

Registration Number: NCT04639310

Locations: 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Anne & Robert H. Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy